Clinical Trials on Carcinoma, Merkel Cell in United States

Total 22198 results

National Cancer Institute (NCI)

Recruiting

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade Glioma

United States, Canada, Puerto Rico
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Children With Recurrent Solid Tumors

Sarcoma | Brain and Central Nervous System Tumors | Neuroblastoma

United States, Australia, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

Multiple Myeloma

United States, Canada
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Manchester University NHS Foundation Trust

Completed

Effect of Implant Position on Magnetic Resonance Image Distortion

Neurofibromatosis Type 2

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Carcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States, Ireland
University of Alabama at Birmingham
Genentech, Inc.

Completed

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Neurofibromatosis Type 2 | Progressive Vestibular Schwannomas

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer (PCW)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer

United States, Guam
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])

Neuroblastoma

United States, Canada
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Switzerland
Nationwide Children's Hospital
Pfizer

Not yet recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | WHO Grade III Glioma | WHO Grade IV Glioma | Infant Type Hemispheric Glioma | Diffuse Midline Glioma, H3K27-altered

United States, Australia, Canada, Germany, Netherlands
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Gestational Trophoblastic Tumor | Neurotoxicity | Peripheral Neuropathy

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Adult T Acute Lymphoblastic Leukemia | Childhood T Acute Lymphoblastic Leukemia | Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | Ann Arbor Stage III Adult Lymphoblastic Lymphoma | Ann Arbor Stage III Childhood Lymphoblastic Lymphoma | Ann... and other conditions

United States, Canada, Australia, New Zealand
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; Celgene Corporation

Active, not recruiting

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

United States
National Tuberous Sclerosis Association

Recruiting

TSC Biosample Repository and Natural History Database

Tuberous Sclerosis | Lymphangioleiomyomatosis

United States, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma and Brain Metastases

Canada, United States, Australia, France, Germany, Italy, Spain
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

Neurotoxicity | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Adult Diffuse Astrocytoma | Adult Mixed Glioma | Adult Oligodendroglioma | Seizure

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

Leukemia | Neurotoxicity | Long-term Effects Secondary to Cancer Therapy in Children | Psychosocial Effects of Cancer and Its Treatment

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Celgene

Completed

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Multiple Myeloma

Belgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Recurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Brain and Central Nervous System Tumors

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER (BALANCE)

PSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
University of Birmingham
University of Leeds; Jazz Pharmaceuticals; The Brain Tumour Charity

Recruiting

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT)

Glioblastoma | Brain Tumor | Cannabis | Brain Tumor, Recurrent

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
European Organisation for Research and Treatment...
Anticancer Fund, Belgium; Rising Tide Foundation

Recruiting

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (OligoRARE)

Melanoma | Sarcoma | Head and Neck Cancer | Gynecologic Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Bladder Cancer | Skin Cancer | Colon Cancer | Renal Cancer | Oligometastasis | Hepatobiliary Cancer | Upper Urinary Tract Carcinoma

Italy, France, Belgium, Switzerland, United Kingdom, Poland, Germany
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Leukemia

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
King's College London

Recruiting

The Living With a Long-Term Condition Study (LTC)

Liver Diseases | Heart Diseases | Heart Failure | Stroke | Cerebrovascular Disorders | Epilepsy | Pain | Multiple Sclerosis | Hypertension | Obesity | Diabetes | Cancer | Arthritis | Osteoarthritis | Rheumatoid Arthritis | Parkinson Disease | Migraine | Hepatitis | Atrial Fibrillation | Asthma | Endometriosis | Dementia | Fibromyalgia | Celiac... and other conditions

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
Cyclo Therapeutics, Inc.

Recruiting

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 (TransportNPC)

Niemann-Pick Disease, Type C1

United States, Spain, Israel, Taiwan, Brazil, Germany, Australia, Poland, Turkey, Italy, United Kingdom
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

United States, United Kingdom, Sweden, Belgium, Netherlands, Germany, Spain, Norway, Poland, France, Italy, Canada, Denmark, Portugal
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
University of Leeds
Hoffmann-La Roche; University of Oxford

Terminated

TARGET GCAT Registry

Giant Cell Arteritis

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
Syndax Pharmaceuticals

Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
Children's Cancer and Leukaemia Group

Unknown

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

Brain and Central Nervous System Tumors

United Kingdom, Ireland
University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Ariad Pharmaceuticals

Approved for marketing

Expanded Access Program of Ponatinib

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Recurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 Glioma

United States, Canada

Clinical Trials on Carcinoma, Merkel Cell in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations